Core Viewpoint - Johnson Fistel, PLLP is investigating RxSight, Inc. for potential violations of federal securities laws related to misleading statements and undisclosed material information to investors [1][3]. Company Overview - RxSight, Inc. is facing scrutiny regarding its business outlook and product adoption trends, particularly after reporting significant declines in Light Delivery Device (LDD) sales and total revenue for Q2 2025 [3]. Financial Performance - On July 9, 2025, RxSight released preliminary financial results indicating notable declines in LDD sales and usage of its light adjustable intraocular lenses (LALs) [3]. - The company revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint, attributing this to "adoption challenges over the last few quarters" [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether RxSight misled investors about its financial performance and future prospects [3]. - Investors who purchased RxSight securities and incurred losses may be eligible to participate in the investigation [2]. Whistleblower Information - Individuals with nonpublic information about RxSight are encouraged to assist with the investigation or explore options under the SEC Whistleblower Program, which may offer rewards of up to 30% of any successful enforcement action [4]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with a strong track record in securing recoveries for clients [5][6].

Core Insights - The integration of generative AI and agentic AI in medical devices is transforming clinical workflows and patient care, with generative AI focusing on content creation and design optimization, while agentic AI enables autonomous decision-making based on real-time data [1][3] Group 1: AI Integration in Medical Devices - Generative AI is used to create synthetic medical images for training diagnostic tools, enhancing datasets [1] - Agentic AI supports predictive maintenance in medical equipment, reducing downtime through fault detection and automated service scheduling [3] - AI-powered tools like Nuance Communications's Dragon Ambient eXperience improve clinical documentation by transcribing doctor-patient conversations into structured notes [2] Group 2: Key Factors Driving AI Adoption - There is a rising demand for precision and personalized medicine, with AI enabling individualized diagnostics and treatments based on patient-specific data [5] - The regulatory environment is favorable, with over 700 AI-enabled devices approved by the FDA, significantly increasing from 2020 [6] Group 3: Medical Device Stocks to Watch - Boston Scientific Corporation (BSX) is investing in AI for improved procedural outcomes, with a projected 2025 sales growth rate of 16.4% and earnings expected to grow by 15.9% [8][7] - Johnson & Johnson (JNJ) employs AI in surgical robotics and digital surgery analytics, with a historical earnings growth rate of 5.5% and projected sales growth of 2.8% for 2025 [11][10] - GE HealthCare Technologies Inc. (GEHC) leads in FDA-cleared AI devices, with a projected sales growth rate of 3.2% for 2025 and a focus on enhancing imaging through AI solutions [13][12]

TORONTO and GLIL YAM, Israel, July 11, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce the filing and effectiveness of a shelf registration statement (the "Shelf Registration") on Form F-3 with the Securities and Exchange Commission ("SEC").The Shelf Registration will allow the Company to offer and sell, from time to time, up to an aggregate of $50 million of its common shares, wa ...

Core Insights - The report titled "North America Cystoscopes Market Outlook to 2033" provides a comprehensive analysis of the cystoscopes market in North America, covering various segments including Flexible Non-Video (Fibre) Cystoscopes, Flexible Video Cystoscopes, and Rigid Non-Video (Fibre) Cystoscopes [2][5]. Market Overview - The report includes annualized market revenues, volume, and average pricing data from 2018 through 2033 for each market segment, offering insights into market trends and forecasts [7]. - It provides detailed market data including value in USD, volume in units, and average prices across significant market segments [2][7]. Market Segmentation - The report segments the market into three main categories: Flexible Non-Video (Fibre) Cystoscopes, Flexible Video Cystoscopes, and Rigid Non-Video (Fibre) Cystoscopes, allowing stakeholders to identify key growth areas [7][8]. - Specific data on the Canadian and Mexican markets is also included, detailing revenue, volume, and average pricing from 2018 to 2033 [8][13]. Strategic Insights - The report aims to empower industry stakeholders to make strategic decisions by providing critical data and analysis necessary for navigating the evolving landscape of the North America Cystoscopes Market [5]. - It highlights the importance of crafting robust business strategies by identifying key market segments anticipated for notable growth in the coming years [7]. Company Profiles - The report includes global corporate-level profiles of significant players in the North America Cystoscopes Market, such as Olympus Corp, KARL STORZ SE & Co KG, and Stryker Corp, among others [11][14]. - Company share and distribution share data specific to the Cystoscopes Market for 2023 is also provided, offering insights into competitive positioning [7][13].

Core Insights - The report titled "North America Ureteroscopes Market Outlook to 2033" provides a comprehensive analysis of the ureteroscopes market in North America, focusing on various segments including Flexible Non-Video (Fibre) Ureteroscopes, Semi Rigid Ureteroscopes, and Flexible Ureteroscopes [1][4]. Market Overview - The report includes detailed data on market value (USD), volume (units), and average prices (USD) for different segments of the ureteroscopes market [1][4]. - It covers annualized market revenues from 2018 to 2033, providing insights into revenue trends and projections [4][5]. Regional Analysis - The report segments the ureteroscopes market by country, specifically analyzing the markets in Canada, Mexico, and the United States [3][4][7]. - For each country, the report provides revenue, volume, and average price data from 2018 to 2033, along with distribution share and company share data for 2023 [4][6][10]. Competitive Landscape - The report profiles key companies operating in the North America ureteroscopes market, including Boston Scientific Corp, KARL STORZ SE & Co KG, and Olympus Corp, among others [8][10]. - It discusses business strategies and market positioning of these companies, identifying key segments poised for growth [4][8]. Strategic Insights - The report outlines market-entry and expansion strategies, as well as competition strategies by identifying market leaders and their positions [4][5]. - It emphasizes the importance of understanding distribution channels and preferred modes of product distribution to capitalize on market opportunities [4].

One of the good things about the healthcare sector is that most medical care isn't optional. This is the foundation behind the sector, but on that foundation sits the growth opportunity that comes with medical advances.Right now one of the best healthcare stocks to look at is medical device giant Medtronic (MDT 0.39%), which is offering a historically high 3.2% dividend yield.Here's why you might want to invest $1,000 in it right now, a sum that will allow you to buy roughly 11 shares. What Medtronic has to ...

All right. Do you have her. Are you holding her.Child birth, the biological miracle, is now being performed by robots. That's Mama An. She actually gives birth.Meet Mama An. She's a mannequin with robotic elements that simulate birth for nursing students like those in this class in Rhode Island. It's so realistic to work with these mannequins.They have real lung sounds, heart sounds. They can even bleed and simulate other potential birthing complications like preeclampsia. Help. Help.One of the trainers pro ...

Core Viewpoint - Zynex, Inc. is under investigation for potential claims related to a class action complaint alleging that the company's board of directors breached their fiduciary duties by misleading investors about financial performance and operational practices [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint claims that Zynex's management engaged in practices that artificially inflated the company's stock price through false statements regarding financial performance and compliance with insurance reimbursement policies [2]. - It is alleged that Zynex operated a systemic "oversupplying scheme," shipping excessive quantities of supplies to patients and billing insurers significantly more than necessary [2]. Financial Impact and Regulatory Scrutiny - The extent of Zynex's misconduct was revealed on March 11, 2025, when the company announced a revenue shortfall due to slower payments from insurers, particularly Tricare, which accounted for 20-25% of its annual revenue [3]. - Following the announcement, Zynex's stock price fell by $3.59 per share, or 51.3%, closing at $3.41 per share, indicating a severe loss of shareholder value and highlighting the company's exposure to regulatory and financial risks [4].

Company Performance - Pacific Biosciences of California (PACB) closed at $1.50, with a daily increase of +1.35%, outperforming the S&P 500's gain of 0.28% [1] - The stock has increased by 27.59% over the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Expectations - Analysts expect Pacific Biosciences to report earnings of -$0.18 per share, reflecting a year-over-year growth of 10% [2] - The revenue forecast for the upcoming quarter is $36.46 million, indicating a growth of 1.26% compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at -$0.64 per share and revenue at $155.12 million, showing changes of +22.89% and +0.72% respectively from the previous year [3] Analyst Sentiment - Recent adjustments to analyst estimates indicate positive sentiment towards Pacific Biosciences' business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses stock performance based on estimate changes, currently ranks Pacific Biosciences as 1 (Strong Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 173, placing it in the bottom 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.79, reflecting a -2.53% change from the previous day's closing price, underperforming the S&P 500's daily gain of 0.28% [1] - The stock has increased by 13.19% over the past month, outperforming the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Projections - The upcoming EPS for Ginkgo Bioworks is projected at -$1.44, indicating a 55.00% increase compared to the same quarter last year [2] - Quarterly revenue is estimated at $43 million, which is a decrease of 23.5% from the year-ago period [2] - For the entire year, the Zacks Consensus Estimates forecast earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively compared to the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Ginkgo Bioworks are important as they reflect short-term business trends and can indicate analyst optimism about the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, provides an actionable rating system for investors [5] - Ginkgo Bioworks currently holds a Zacks Rank of 2 (Buy), with the consensus EPS estimate remaining unchanged over the last 30 days [6] Industry Context - Ginkgo Bioworks is part of the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - The top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1 [7]